GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (OTCPK:THMO) » Definitions » EPS (Diluted)

THMO (ThermoGenesis Holdings) EPS (Diluted) : $-5.14 (TTM As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings EPS (Diluted)?

ThermoGenesis Holdings's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.46. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.14.

ThermoGenesis Holdings's EPS (Basic) for the three months ended in Mar. 2024 was $-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.14.

ThermoGenesis Holdings's EPS without NRI for the three months ended in Mar. 2024 was $-0.46. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.54.

During the past 3 years, the average EPS without NRIGrowth Rate was 61.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 51.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 48.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, ThermoGenesis Holdings's highest 3-Year average EPS without NRI Growth Rate was 79.20% per year. The lowest was -278.00% per year. And the median was 13.45% per year.


ThermoGenesis Holdings EPS (Diluted) Historical Data

The historical data trend for ThermoGenesis Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings EPS (Diluted) Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -151.20 -117.00 -43.41 -20.45 -7.59

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.07 -0.91 -1.44 -2.33 -0.46

Competitive Comparison of ThermoGenesis Holdings's EPS (Diluted)

For the Medical Devices subindustry, ThermoGenesis Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's PE Ratio falls into.



ThermoGenesis Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

ThermoGenesis Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-17.975-0)/2.368
=-7.59

ThermoGenesis Holdings's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.856-0)/4.026
=-0.46

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (OTCPK:THMO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ThermoGenesis Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings Business Description

Traded in Other Exchanges
N/A
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
Executives
Xiaochun Xu director 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu director 2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu director 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph director MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford director 7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate director 350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble officer: Principal Accounting Officer 2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu director
Boyalife Investment Inc. 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545